Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 2,401–2,500 of 2,517
Sinz, A., Ianni, A. D., Ihling, C. H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2271015/v1
Sait, S., & Vaisman, I. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522606
“The study identifies two protein structures (1TSR and 4IBY) (Cho et al. 1994; Eldar et al. 2013) that vary in resolution, which can be useful for studying comprehensive mutagenesis to determine the effect of differences in protein structures on functional predictions of protein mutants.”
BackgroundBourmoum, M., Radulovich, N., Tsao, M., & Pelletier, L. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.13.528233
Data from Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells
Guida, E., Bisso, A., Fenollar‐Ferrer, C., Napoli, M., Anselmi, C., Girardini, J. E., Carloni, P., & Sal, G. D. (2023) · doi:10.1158/0008-5472.c.6496331.v1
Deneka, A. Y., Baca, Y., Serebriiskii, I. G., Nicolas, É., Parker, M. I., Nguyen, T. T., Xiu, J., Korn, W. M., Demeure, M. J., Wise-Draper, T. M., et al. (2023) · doi:10.1158/1078-0432.c.6532500
Jordan, J. J., Inga, A., Conway, K., Edmiston, S. N., Carey, L., Wu, L., & Resnick, M. A. (2023) · doi:10.1158/1541-7786.c.6542128
Jordan, J. J., Inga, A., Conway, K., Edmiston, S. N., Carey, L., Wu, L., & Resnick, M. A. (2023) · doi:10.1158/1541-7786.c.6542128.v1
Choe, J. H., Kawase, T., Xu, A., Guzman, A., Obradović, A., Low-Calle, A. M., Alaghebandan, B., Raghavan, A., Long, K., Hwang, P. M., et al. (2023) · doi:10.1158/2159-8290.c.6603190
Spary, L. K., De‐loyde, K., Roberts, H., Martin, F., Lee, C. P., Butler, R., Mason, M. D., Thomas, G. A., Parry-Jones, A., & Adams, R. (2023) · Journal of Cancer Therapy · doi:10.4236/jct.2023.147027
“These mutations are distributed within exon 4-9 which encode the DNA-binding domain [45].”
BackgroundDixit, U., Pandey, V., Comollo, T. W., Upadhyay, A. K., & Pandey, V. N. (2023) · Research Square · doi:10.21203/rs.3.rs-3299317/v1
Titania nanosheets induce anticancer activityin human non-small cell lung cancer cells
Soonnarong, R. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.300
Dixit, U., Pandey, V., Comollo, T. W., Upadhyay, A. K., & Pandey, V. N. (2023) · Indian Journal of Biochemistry and Biophysics · doi:10.56042/ijbb.v60i11.5393
Restoration of Tumor Suppression to Cancer Carrying p53 Mutations
Amin, M. N., & Liu, Y. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003642 · Cited by 1
p53 Protein Represses the E6 Promoter Activity of Human Papillomavirus Type 59
Rho, J., Kim, D. W., & Choe, J. (1996) · Molecules and Cells · doi:10.1016/s1016-8478(23)07321-1
Significant value of p53 accumulated in Invasive Ductal Breast CarcinomaPreprint
Baccouche, S., Rebaï, A., Frikha, M., Daoud, J., JLIDI, R., & Gargouri, A. F. (2024) · Research Square · doi:10.21203/rs.3.rs-4010877/v1
Molecular Dynamics Simulation of the Interaction of Saccharin with Human p53 Protein
Shahlaei, M., & Mansourian, M. (2023) · Armaghane Danesh · doi:10.61186/armaghanj.28.6.11
Zhao, L., Punga, T., & Sanyal, S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.23.604790
“The core domain contains a hydrophobic core of β -sandwich, which consists of two antiparallel β -sheets with four strands (S1, S3, S8, and S5) and five strands (S6, S7, S4, S9, and S10), respectively ( Cho et al., 1994 ; Figure 1—figure supplement 1A ).”
Intrinsically disordered proteins
Schweitzer‐Stenner, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15964-0.00008-6
Gómez, S. V., Garro, J. M. M., Ortiz, L. D., Flórez, J. E. S., Monroy, F. P., & Sánchez, R. G. P. (2024) · Biomedicines · doi:10.3390/biomedicines12102287
“Structural studies have demonstrated the presence of Zn ions in its active site [57] and the importance of these metal ions in the following functions has been verified: binding of the DNA-binding domain (DBD) to DNA occurs only in the presence of Zn; the absence of Zn decreases the activity of the…”
BackgroundCovalent Modification of p53 by (E)-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
Brown, K. M., Robello, M., Perciaccante, A. J., Dinan, J. C., Maity, T. K., Lyons, G. C., Kumar, J. P., Durell, S. R., Tagad, H. D., Schilling, D., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00447
(2000) · Time to knit · doi:10.1016/s0024-7804(99)80008-6
10.1016/b978-1-4557-4696-5.00074-9
(2000) · Time to knit · doi:10.1016/b978-1-4557-4696-5.00074-9
Chiu, C. A., Stetson, S., & Thayer, K. M. (2025) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c08495
“The crystal structure PDBID 1TUP 34 details the DNA binding domain interface interacting with a cognate DNA sequence.”
Opto-p53: A Light-Controllable p53 Signaling for Regulating p53-Dependent Cell FatePreprint
Tsuruoka, T., Goto, Y., & Aoki, K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647217
“4A) (Candau et al. , 1997; Cho et al. , 1994; Joerger et al. , 2005; Lin et al. , 1994; Teufel et al. , 2007; Zhu et al. , 1998).”
Zhao, L., Punga, T., & Sanyal, S. (2025) · eLife · doi:10.7554/elife.106469.1
Rauniyar, K., Milon, T. I., Khajouie, P., Alabdulkarim, R., Chen, Y., Kondra, S., Raghavan, V. V., & Xu, W. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70005
Djenhi, F., Bensouıcı, C., Kechebar, M. S. A., Fernández, M. J. F., Atoki, A. V., Karoune, S., Boumechhour, A., Mustapha, M. A., Saadoun, S., Hamdi, M., et al. (2025) · Natural Product Communications · doi:10.1177/1934578x251350086
“The results show that, for petals extracts, the presence of Heptacosane, Linoleic acid, and Nonacosane as main components is in partial agreement with the previous study; 21 in fact, their amounts are respectively 14.33, 11,37, and 9,93% against 2,96, 3,21, and 26,21% in our study.”
InfluentialCognate DNA inhibits p53 aggregation but fails to rescue key hotspot mutants
Steinsaltz, M., Gomes, G.-N. W., & Levine, Z. A. (2026) · Insights in Biochemistry and Molecular Biology · doi:10.1101/2025.07.24.665437
Li-Fraumeni Syndrome-Associated p53 Variants Disrupt Kidney and Urinary Tract DevelopmentPreprint
Romero, A., Davilavaladez, A., Blackburn, A. T. M., Kinua, A. G., Srivastava, Y., Evans, D. G., Bancroft, E. K., Eeles, R. A., Corkins, M. E., & Miller, R. K. (2025) · medRxiv · doi:10.1101/2025.08.29.25333303
Uzaif, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-8085560/v1
Stetson, S., Mancía, F. C., & Thayer, K. M. (2025) · ACS Omega · doi:10.1021/acsomega.5c05639 · Cited by 3
Cancers modulate p53 truncal neoantigen display to evade T cell detectionPreprint
Haratani, K., Reinhold, B. B., Duke‐Cohan, J. S., Fahey, C. G., Tan, K., Mallis, R. J., Gusev, A., Kehl, K. L., Luo, J., Holliday, E. L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690562
Poyraz, E. B., Rouzi, K., Gül, L. B., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.145004
Navigating the labyrinth of drugging the disordered
Tolani, S., Mitra, D., Dantu, S. C., & Kumar, A. (2025) · Biophysical Reviews · doi:10.1007/s12551-025-01391-x · Cited by 2
“Initial structure characterization in 1994 revealed a well-folded domain which was identified as the DNA binding domain (Cho et al. 1994).”
Bloom, B. R., Iden, C. R., & Mastrangelo, I. A. (1998) · Springer eBooks · doi:10.1007/978-94-015-9046-4_17
Facci, P. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-3142-8.00008-x
Posttranslational Modifications of p53: Upstream Signaling Pathways
Anderson, C. W., & Appella, E. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_5
“The structure of the DNA binding domain (DBD), residues 102–292, in complex with DNA, has been determined by X-ray crystallography (Cho et al., 1994) and NMR analysis (Rippin et al.”
MethodSalvage enzymes in nucleotide biosynthesis
Kosinska, U. (2007) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences))
Targeting the p53/MDM2 Pathway for Cancer Therapy
Klein, C., & Vassilev, L. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_2
Milczarek, G. J. (1997) · UA Campus Repository (The University of Arizona)
Novel concepts in MDM2 protein regulation
Worrall, E. G. (2009) · ERA
Analysis of sun-damaged skin and epidermal p53 clones.
Bäckvall, H. (2003) · Uppsala University Publications (Uppsala University)
Pathophysiological impact of targeting the ROS-p53 axis
Sayin, V. I. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor
Donehower, L. A., Bocangel, D., Dumble, M. L., & Lozano, G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_8
“The p53R175H mutation alters the conformation of the p53 protein and is a common hot spot mutation present in 6% human cancers and in patients with Li-Fraumeni syndrome (Cho et al., 1994; Frebourg et al., 1995; Hussain and Harris, 1998).”
Backgroundde Oliveira, J. G. (2008) · Aleph UCLA Undergraduate Research Journal for the Humanities and Social Sciences
Involvement of Nitric Oxide(NO) to disease state.
秀樹, 森. (1995) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.57.1127
Signalling to the C-terminus of p53
Cain, C. R., Shieh, S.-Y., & Prives, C. L. (1997) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8934-6_2
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144525
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144495
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144510
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144483
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144501
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144486
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144480
Qin, K., Helei, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144489
Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144498
Kim, J., Jeong, K., Jun, H., Kim, K., Bae, J. M., Song, M. G., Yi, H., Park, S., 우고운, Lee, D.-W., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26559497
Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144474
Qin, K., Hou, H., Liang, Y., & Zhang, X. (2020) · Figshare · doi:10.6084/m9.figshare.12144516
Gracia, L. D. (2025) · Revista Multidisciplinar Epistemología de las Ciencias · doi:10.71112/06eh8813
Tracewell, M., Shankle, H. N., Barnada, S. M., Vyas, K. S., Kim, K. M., Qyshkollari, T., Karlin, J., Barta, J. A., & McMahon, S. B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.14.705936
“As a sequence-specific transcription factor, wild-type p53 function relies on a highly structured central domain in which several amino acids make direct hydrogen bonds with DNA [8-10].”
Uzaif, Q. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00578-8
“E3 ubiquitin ligase MDM2 interacts with the N-terminal transactivation domain of p53, facilitating its ubiquitination and proteasomal deg-radation—thus ensuring balanced control over p53 stability and function (Cho et al. 1994).”
Quantum chemical profiling of protein mutations via fragment-based DFT
Leyva, A., & Niazi, M. K. K. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1770157
barsagade, P. (2026) · Research Square · doi:10.21203/rs.3.rs-8914143/v1
Mapping Allosteric Communication in the Nucleosome with Conditional Activity
Onyema, A. C., Dikeocha, C., Patel, R., Moussa, J. E., & Loverde, S. M. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00317 · Cited by 1
UBE2C-orchestrated ubiquitination networks in cancer progression and therapy resistance
Su, N., Pan, Z., Feng, X., Wang, H., & Wang, L. J. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153550 · Cited by 2
Wu, L., Zou, Z., Li, Y., Hao, X., Zhang, J., Ying, J., Xing, P., & Li, J. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70262
“…domains: the N-terminal transactivation domain (TAD, residues 1–61), the proline-rich domain (PRD, residues 64–92), the central DNA-binding domain (DBD, residues 96–292), the tetramer-ization domain (TET, residues 324–356), and the C-terminal regulatory domain (CTD, residues 364–393) [6, 7].”
de Abreu, P. A. (2016) · theses.fr (ABES) · doi:10.70675/a49b7f77z1189z425fz86b8z8ee9f8fa327a
“Indeed, it is the most frequently mutated gene in cancer (more than 50% of all human cancer) with most of these mutations localized in the DNA biding domain (Cho et al., 1994; Lane, 1992).”
Zhao, Z., Wang, G., & Qian, Z. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d6cp00665e
Malhab, L. J. B. (2016) · theses.fr (ABES) · doi:10.70675/a9a79207z0857z4ed5zb207z749cdceb9430
Syndrome de Li-Fraumeni,Corticosurrénalomes et autres tumeurs pédiatriques
Renaux‐Petel, M. (2020) · theses.fr (ABES) · doi:10.70675/d4c4441az88bcz45bezbcafz2529a515c966
Développement d'un biosenseur fluorescent d'un mutant de p53 sujet à l'agrégation dans les cancers
Pellerano, M. (2019) · theses.fr (ABES) · doi:10.70675/f84edc5bz284az4a6cz9cf3z934f0180c259
“Type de mutants Sur la base de la structure cristalline du domaine de liaison à l’ADN de p53 en complexe avec l'ADN, les mutants ont été classés en deux catégories : les mutants de contact, où l’acide aminé muté est un acide aminé directement lié à l’ADN (ex : R248W, R273H ou R273C) et les mutants structurels qui comp…”
BackgroundInfluentialRegulation of Netrin-1 by p53 isoforms
Sun, Y. (2020) · theses.fr (ABES) · doi:10.70675/814a2023zacd3z4475z897dz6ee94580c5a3
Reyes, J. (2026) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5281/zenodo.18892592
Influence of centrosome amplification on the response to chemotherapy in epithelial ovarian cancer
Fantozzi, G. (2023) · theses.fr (ABES) · doi:10.70675/9023fab1z003az407bz9b02z2054939e787d
Yang, L., Cui, Y., Cui, S., et al. (2026) · Biophysical Chemistry · doi:10.1016/j.bpc.2026.107627
A catalogue of missense and nonsense mutation abundances for the U.S. cancer patient populationPreprint
Arun, A. S., Liarakos, D., Mendiratta, G., McFall, T. B., Hargreaves, D. C., Wahl, G. M., Hu, J., & Stites, E. C. (2026) · medRxiv · doi:10.64898/2026.04.20.26351248
Zhou, H., Zhou, T., & 晏世伟 (2026) · The Journal of Chemical Physics · doi:10.1063/5.0328162
“The LSH motif and L3 loop form the DNA-binding interface of p53: residues from the LSH motif interact with the major groove of DNA, while residues from the L3 loop engage with the minor groove [5, 12, 13].”
Ahamada, F., Ndong, A., Samb, M. D., Mbaye, F., & Sembene, M. (2026) · International Journal of Genetics and Genomics · doi:10.11648/j.ijgg.20261402.13
Iizumi, M. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014168
“The p53 core DNA-binding domain was modeled from 1TSR [12], using chain B for the protein and DNA chains E/F for protein–DNA distance calculations.”
The Biology of Hypomorphic TP53 Variants and Implications for Clinical Management
Moses, R., Powers, J. M., Schwartz, A., Garber, J. E., MacFarland, S. P., Rana, H. Q., Murphy, M. E., & Maxwell, K. N. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4543 · Cited by 1
Burgazlı, A. Y., Avuloğlu-Yılmaz, E., Mamur, S., et al. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2026.2691542
“…in DNa double-strand break responses (stakyte et al. 2021), and tumor Protein p53 (p53) as a master regulator of cell fate under genotoxic stress (cho et al. 1994; liu et al. 2024). additionally, the Phase ii detoxification enzyme glutathione s-transferase (gst) (Prade et al. 1997; aloke et al.…”
Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms
Hershberger, K. K., Thibodeau, J., Su, Y., Ramakrishna, S. S. M., Singh, V., Sharma, A., Edwards, H. J., Ge, Y., & Yang, J. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118177
Flavonoids as inhibitors of the cell cycle in cancer
Kashyap, D., Sharma, R., Munda, V. S., Garg, V. K., Thakur, S., Sharma, D., Okpala, C. O. R., & Dhiman, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-42855-5.00006-6
LFPM inhibition of RING1-mediated p53R175H degradation drives oncogenesis in p53R175H-mutant cancers
Li, X., Wang, B., Wang, Z., Li, Y., Li, Y., Gao, Y., & Wang, X. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-026-01805-7
The role of mutant p53R175H in de novo activation of von Willebrand factor expression in tumor cells
Seyyedi, N., Lo, C. S., Alavi, P., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.07.005
T253X Mutations Alter Local Structure and Trigger Tyr236 Hydration in p53 DNA-Binding Domain
Imam, I. A., Holcomb, N., Ellingson, S. R., D'Orazio, J. A., & Shao, Q. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c01875
Maimaitituerhong, M., Xiao, J., Gao, W., Zheng, R., 范亚阁, Zhang, R., Wang, Y., Deng, F. M., & Xia, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1921345
“Structural disruption of the DBD impairs sequence-speci fi c DNA binding and compromises the transcriptional activation of critical tumor suppressor pathways, including apoptosis, cell-cycle arrest, and DNA damage responses (19, 20).”
Rufus, A. C., Sidharth Kumar, N., Ramasamy, M., & Elangovan, E. (2026) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2026.1875897
“In this variant, the loss of the positively charged Arginine side chain at residue 273 prevents the formation of critical electrostatic contacts with the DNA phosphate backbone, thereby abolishing transcriptional activity without inducing global unfolding (Cho et al., 1994).”
Loganathan, T., Madhulekha, S., Shree Devi, M. S., & Doss, C. G. P. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103741
Maru, B., Shah, A. P., Parmar, G. R., Rekha, A., & Pandey, S. N. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-026-05901-9
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.